Your browser version may not work well with NCBI's Web applications. More information here...
1: J Biol Chem. 2005 Aug 12;280(32):29186-93. Epub 2005 Jun 7.Click here to read Links

The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity.

Division of Clinical Chemistry and Biochemistry, Department of Pediatrics, Steinwiesstrasse 75, 8032 Zurich.

Head and neck squamous cell carcinoma express high levels of the EF-hand calcium-binding protein S100A2 in contrast to other tumorigenic tissues and cell lines where the expression of this protein is reduced. Subtractive hybridization of tumorigenic versus normal tumor-derived mammary epithelial cells has previously identified the S100A2 protein as potential tumor suppressor. The biological function of S100A2 in carcinogenesis, however, has not been elucidated to date. Here, we report for the first time that during recovery from hydroxyurea treatment, the S100A2 protein translocated from the cytoplasm to the nucleus and co-localized with the tumor suppressor p53 in two different oral carcinoma cells (FADU and SCC-25). Co-immunoprecipitation experiments and electrophoretic mobility shift assay showed that the interaction between S100A2 and p53 is Ca(2+)-dependent. Preliminary characterization of this interaction indicated that the region in p53 involved with binding to S100A2 is located at the C terminus of p53. Finally, luciferase-coupled transactivation assays, where a p53-reporter construct was used, indicated that interaction with S100A2 increased p53 transcriptional activity. Our data suggest that in oral cancer cells the Ca(2+)- and cell cycle-dependent p53-S100A2 interaction might modulate proliferation.

PMID: 15941720 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Hydroxyurea (Droxia® , Hydrea® )

    Your doctor has ordered hydroxyurea to help treat your illness. Hydroxyurea comes as a capsule to take by mouth.